Prime Medicine (PRME) Stock Analysis

What Prime Medicine does

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

Key metrics

ETFs linked to PRME

Broad-market and Healthcare sector ETFs an investor holding Prime Medicine is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PRME fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Prime Medicine?

Prime Medicine trades under the ticker PRME on NASDAQ.

Which exchange is PRME listed on?

PRME is listed on NASDAQ.

What sector does Prime Medicine operate in?

Prime Medicine is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PRME in a portfolio?

PortView shows PRME's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.